Why Did Warren Buffett Buy More Shares of This Healthcare Company?

In a Form 3 filing issued with the SEC earlier this morning, Warren Buffett’s Berkshire Hathaway Inc. (NYSE:BRK.A) (NYSE:BRK.B) disclosed that it now owns more than 10% of dialysis services provider DaVita Inc. (NYSE:DVA). The move increased Buffett’s total holdings of DaVita to 10.2 million shares, with the most recent transaction amounting to little over 280,000 shares worth $29.7 million. The “Oracle of Omaha” now holds a whopping $1.1 billion in DaVita stock. Here’s a complete look at Warren Buffett’s holdings.

Warren BuffettIn early morning trading following the release, shares of the company were up almost 1.5%. Before you write off these gains as purely speculative, it’s important to remember that empirical studies have proven that individual investors who mimic or “monkey,” the world’s most successful hedge fund managers can beat the market by 7 percentage points a year. Therefore, it’s worth looking into a potential motive behind Buffett’s bullish DaVita bet.

Since the start of 2012, DaVita has been a solid investment, returning 37.8%. This appreciation has outpaced the medical care industry’s average (23.8%), and competitors Baxter International Inc. (NYSE:BAX) at 22.6%, and Fresenius Medical Care AG & Co. (NYSE:FMS) at 10.3%. Over this same time, DaVita has reported generally impressive earnings, beating the Street’s estimates in three straight quarters. This streak is longer than that of Baxter, which has beat analyst forecasts in two straight quarters, but below similarly-sized peers like Fresenius, HCA Holdings Inc (NYSE:HCA), and Tenet Healthcare Corporation (NYSE:THC).

In its most recent earnings release, DaVita reported an EPS of $1.49, beating consensus by 2 cents, even though the company experienced larger than expected second quarter losses related to its international expansion efforts. CEO Kent Thiry called the period “rock-solid,” claiming that his company “perform[ed] well clinically, operationally and strategically.”

Part of DaVita’s international expansion plan includes partnering with medical organizations in Southeast Asia, Europe, and the Middle East to bring affordable dialysis care to patients of all nationalities. Most of the company’s costs related to this activity stems from the legal and professional service fees needed to close the deal on partnerships and acquisitions. These expenses totaled $12 million in the past quarter, and the company expects to lose $30 million by the end of this year, though execs state “international expansion is a long-term growth activity, it will require … continued losses in the short term.”

Most likely, Buffett is optimistic that these expansion plans will help DaVita generate solid earnings appreciation going forward. Early estimates expect the company to average EPS growth of 12.3% a year over the next half-decade. This is decidedly more impressive than its aforementioned competitors, as Baxter (8.5%), Fresenius (10.5%), HCA Holdings (10.9%), and Tenet Healthcare (12.2%) all have lower expected EPS growth.

From a valuation standpoint, we can see that investors are not overpaying for DaVita’s earnings potential, as the company’s stock sports a PEG ratio of 1.54; typically any figure between 1 and 2 indicates shares are trading at a fair price. More interestingly, DaVita is actually cheaper than the likes of Baxter, Fresenius and Tenet Healthcare, which trade at an average PEG of 2.36. Only HCA Holdings, which trades at a PEG of 0.48, is a better value.

One final point worth mentioning is that DaVita appears to have the first step on its competitors due to its advantageous operational efficiency. Over the past twelve months, the company has averaged operating (16.1%) and net (6.9%) margins far above the industry averages (12.4%, 4.3%), indicating that Buffett is most likely a fan of DaVita’s superior cost-saving abilities.

While DaVita is expecting double-digit earnings expansion in a time when the majority of other companies operating in the medical care industry are predicting much less, the biggest reason to be bullish on this stock is that investors can truly buy growth at a reasonable price. Despite DaVita’s gains in 2012 thus far, valuation indicators suggest that more appreciation may be on the horizon, and a boost from Warren Buffett is never a bad thing.

Other fund managers that currently hold DaVita are Andreas Halvorsen’s Viking Global, Stephen Mandel, and Lee Ainslie, though Buffett owns more than twice the number of shares as the next closest fund. For a complete look at the hedge fund industry’s sentiment toward this stock, continue reading here.

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!